Trial Profile
OCV-C01 as a combination therapy of peptide-based cancer vaccines for patients with advanced biliary tract cancer refractory to priortherapy : Phase II study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2021
Price :
$35
*
At a glance
- Drugs OCV C01 (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Biliary cancer; Carcinoma; Gallbladder cancer
- Focus Biomarker; Therapeutic Use
- 01 Mar 2021 Results published in the Anticancer Research
- 02 May 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 07 Feb 2014 New trial record